Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Prospect IPA and Clever Care Collaborates to Provide Vast Health Care Choices for Comprehensive Care


News Image

In times like COVID-19, providing access to care in a timely manner becomes even more critical and our networks provide many options for members to easily get healthcare when they need it.

Clever Care Health Plan, a Medicare Advantage HMO plan focused on delivering Eastern Medicine and comprehensive supplemental benefits, has announced its partnership with Prospect Medical Group, a leading provider in healthcare services. With the goal of providing more accessible health care choices in mind, the addition of Prospect IPAs network of physicians, specialists, and hospitals will enhance Clever Care’s broad network of over 15,000 providers and 50 leading hospitals in Los Angeles, Orange, and San Diego counties. Prospect’s provider facilities can range from cultural care training to patient engagement programs, which are beneficial to the diverse population of Medicare Advantage beneficiaries.

“Through our extensive network of providers, we provide high-quality, personalized care for our members. Providing support to our Medicare Advantage members in a compassionate and culturally sensitive manner is a top priority for us. Clever Health’s unique approach to care compliments our company’s long history of providing the right care for each unique patient” said Jim Brown, CEO, Prospect Medical Systems. “In times like COVID-19, providing access to care in a timely manner becomes even more critical and our networks provide many options for members to easily get healthcare when they need it.”

With about 600,000 members and 28 IPAs in six states, Prospect has a proven record of experience in managing health plan-delegated downside risk for doctors and hospitals. Prospect Medical Group is managed by its affiliate, Prospect Medical Systems, a management services organization with 25 years of experience. Recently, for the ninth year in a row, Prospect and its subsidiaries were given an award for Elite States from America’s Physician Groups (APG) Stands of Excellence Survey 2020.

This partnership will allow both health care companies to deliver a holistic approach to care that offers members extensive provider options that will improve overall access to care. Prospect and Clever Care are both dedicated to making sure their beneficiaries receive the care and support they need; in the language they understand.

Complete Care from East to West

Clever Care makes it possible for people who are eligible for Medicare to get the best of both worlds through advanced Western medicine and traditional Eastern medicine. Their extensive network of providers allows their members to access unique health coverage that includes popular Eastern concepts such as herbal supplements, acupuncture, cupping, and many more. All these features combined with innovative Western medical practices create a comprehensive Medicare Advantage solution that Clever Care is pleased to offer to Southern California residents.

“Our partnership with Prospect helps us deliver increased access to our unique combination of Eastern and Western Medicine to Medicare-eligible patients throughout Southern California. The topic of maintaining a healthy lifestyle is especially significant after knowing the complications that COVID-19 may cause to those with existing health concerns,” said Peter Winston, Vice President of Community and Provider Development at Clever Health Plan “In these unprecedented times, strengthening the connection of physicians and coordination of care is crucial. This partnership will help advance the shared goal of providing the quality care and ensuring coordinated health care services become more available.”

About Prospect Medical Group

The Prospect Medical Group IPAs are managed by Prospect Medical Systems, which develops, implements, and manages a full range of support services. Prospect Medical Holdings, Inc. is the parent company of Prospect Medical Systems. To learn more about Prospect or to select a primary care physician, visit http://www.prospectmedical.com.

About Clever Care Health Plan

Clever Care Health Plan, Inc. is a private company based in Southern California that offers a combination of advanced Western medicine and traditional Eastern medicine. This holistic approach to care is made possible through an extensive network of PCPs and specialists while still maintaining a high quality of care. Detailed information can be found at http://www.CleverCareHealthPlan.com.

Share article on social media or email:

Strategic Financial Solutions Raises over $3,000 To Support Breast Cancer Research


News Image

Strategic Financial Solutions, in honor of Breast Cancer Awareness Month, held its fifth annual Pink Day. This event was created to raise money for breast cancer research. The company announced that it would donate $10 to the Susan G. Komen Foundation for every employee owner who participated in Pink Day by wearing pink for the day.

More than 300 New York City and Buffalo employee owners showed their support by wearing pink and raised $3,150 for the Susan G. Komen Foundation, the world’s leading nonprofit breast cancer organization. The donation will be split evenly between the New York City and Upstate New York chapters of the foundation.

“We know this year looked so different for so many people. Unfortunately, we are reminded that cancer doesn’t wait because of a pandemic. The generous donation from Strategic Financial Solutions’ employees helps more than you know this year,” said Caroline Hurley, Development Manager of Komen Upstate NY. “These dollars help us to support the BOLD goal of reducing breast cancer deaths by 50% by the year 2026 through funding of groundbreaking research, providing treatment assistance for those currently battling breast cancer, and providing the Komen helpline which helps newly diagnosed men and women receive information and support through this time.”

In addition to research and advocacy, Strategic’s donation helps support breast cancer patients through Komen’s other patient-centered services including the Treatment Assistance Program, which helps ease the financial burden of treatment and related costs.

“Strategic has always been committed to supporting causes that strengthen the well-being of our communities. We are proud to again partner with Susan G. Komen and support its efforts to help find a cure for a disease that impacts so many of our clients and employee owners,” said Ryan Sasson, CEO of Strategic Financial Solutions. “I am honored to lead such an empathetic team who care so deeply about each other, their families, and their clients. This shows, yet again, how Strategic is more than a company, it’s a family.”

About Susan G. Komen

Susan G. Komen is the world’s leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow’s cures.

About Strategic Financial Solutions

Strategic Financial Solutions is a leading financial services company that provides comprehensive debt relief solutions for people in difficult financial situations. Through its personalized, tailored approach that includes debt consolidation loans and debt resolution programs, Strategic Financial Solutions has successfully resolved more than $1 billion in debt, and funded loans, for over 100,000 clients. Strategic Financial Solutions has been named one of the fastest-growing companies in New York City twice by Crain’s New York and has been recognized by INC. 500 as one of the fastest-growing private companies in the United States. Strategic ranked 21st in the Best Companies to Work for in New York State program and is a Certified Great Place to Work. More information can be found at http://stratfs.com.

Contact:

Gary Foodim

CMO

Office: (212) 810-4544

Email: gfoodim@stratfs.com

Share article on social media or email:

FDAnews Announces — Medical Device Package and Labeling Compliance Under EU-MDR Webinar Nov. 20, 2020


WCG FDAnews

WCG FDAnews

Medical Device Package and Labeling Compliance Under EU-MDR

An FDAnews Webinar

Wednesday, Nov. 20, 2020, 11:00 a.m.-12:30 p.m. EST

https://www.fdanews.com/mdpackagelabeling

Ready for the EU-MDR changes to labels and packaging? Is one’s quality management system fully integrated to move toward compliance?

This Medical Device Package and Labeling Compliance Under EU-MDR webinar on Nov. 20 will help provide the answers one needs. With expert insights, attendees will gain a better understanding of artwork and labeling compliance and determine how to best move forward.

Bob Tilling, Business Development Manager at Kallik, and Simon Hoffman, Principal Quality Assurance and Regulatory Affairs Consultant, will share tips on meeting the key labeling requirements for the new EU-MDR. They’ll talk about ways companies have managed the transition and implemented systemic solutions for moving forward.

During this webinar, they’ll cover:

  • Key labeling and overall requirements for the EU-MDR
  • Action plans to update artwork and labels for IVDD devices by May 2022 and class IIa and IIb devices by May 2023
  • How other medical device companies have risen to the challenge of compliance by using technology to proof artwork and label regulation changes
  • The transition between the MDD and the MDR
  • Full, systemic solutions that integrate with a quality management system and company operations
  • Ongoing regulatory, industry and customer requirements
  • The best way to achieve full compliance without detriment to customer and patient delivery, avoiding the traditional reactive compliance approach

Get the knowledge needed to ensure packing compliance by registering for this webinar.

Interested in registering multiple sites?

Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally

to learn about our special multisite discount.

Webinar Details:

Medical Device Package and Labeling Compliance Under EU-MDR

An FDAnews Webinar

Wednesday, Nov. 20, 2020, 11:00 a.m.-12:30 p.m. EST

https://www.fdanews.com/mdpackagelabeling

Tuition:

$287 per site

Easy Ways to Register:

Online: https://www.fdanews.com/mdpackagelabeling

By phone: 888.838.5578 or 703.538.7600

About FDAnews:

FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews’ print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations

Share article on social media or email:

Complying with FDA’s Most Recent Guidance Webinar Nov. 13, 2020


WCG FDAnews

WCG FDAnews

Drug, Biologics and Combination Products Labeling:

Complying with FDA’s Most Recent Guidance

An FDAnews Webinar

Friday, Nov. 13, 2020, 11:00 a.m. -12:00 p.m. EST

https://www.fdanews.com/druglabeling

What implications does the Instructions for Use (IFU) guidance have on new drug applications (NDAs) and biologics license applications (BLAs)?

What is needed to modify the content and format for IFUs?

Alan G. Minsk, Esq. — a Partner and Leader of the Food & Drug Practice Team of Arnall Golden Gregory LLP — will clarify the guidance and explain how to comply with it.

During this webinar, attendees will discuss:

  • Why FDA issued the draft guidance and its importance to regulatory, quality and compliance specialists, including the content and format concerns of FDA in general and details necessary for safe and effective use
  • What kind of language IFUs should be written in to be patient friendly
  • What the guidance recommends in terms of voice, commands and sentences
  • Examples of sample labeling that covers all elements of an IFU from dosage and usage to storage and disposal
  • What kinds of recommendations FDA makes in terms of design and layout, such as the use of easy-to-read fonts, sequential numbering and white space
  • Some practical considerations on patient labeling, from a business perspective

If one is at all unclear how to implement this guidance and change IFUs to include what FDA considers to be “clear, concise information that is easily understood,” attend this webinar. One’s NDAs and BLAs depend on it.

Interested in registering multiple sites?

Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally

to learn about our special multisite discount.

Webinar Details:

Drug, Biologics and Combination Products Labeling:

Complying with FDA’s Most Recent Guidance

An FDAnews Webinar

Friday, Nov. 13, 2020, 11:00 a.m. -12:00 p.m. EST

https://www.fdanews.com/druglabeling

Tuition:

$287 per site

Easy Ways to Register:

Online: https://www.fdanews.com/druglabeling

By phone: 888.838.5578 or 703.538.7600

About FDAnews:

FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews’ print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations

Share article on social media or email:

Gateway for Cancer Research in Partnership with Conquer Cancer, the ASCO Foundation Announces $1.5 Million Gateway Discovery Grant


Gateway for Cancer Research

Gateway for Cancer Research

Gateway for Cancer Research, a non-profit organization dedicated to funding transformational cancer research, announces the second annual Gateway Discovery Grant award program in scientific partnership with Conquer Cancer®, the ASCO Foundation.

The Gateway Discovery Grant program was established to identify compelling areas of inquiry in the field of cancer research. This $1.5 million award will be focused on funding innovative clinical trials with the strong potential to address health disparities within underrepresented patient populations.

To help ensure equitable care for all those facing cancer, the Gateway Discovery Grant will support research that aims to mitigate factors such as race, ethnicity, age, gender, geography, education and other socioeconomic indicators that may impact treatment outcomes.

“Gateway is pleased to announce the second annual Discovery Grant in partnership with Conquer Cancer,” said Michael Burton, President and CEO of Gateway for Cancer Research. “Ensuring all patients have access to potentially lifesaving therapies is a critical need, and this award will fund innovative cancer research to advance our vital mission to create a world in which a cancer diagnosis is no longer feared.”

The Phase I or Phase II clinical trial funded by a Gateway Discovery Grant may include the study of any cancer type, and provide three to five years of financial support to talented clinician-scientists poised to deliver research contributing to improved diagnosis and treatment for all cancer patients.

“Our mission to conquer cancer worldwide directs us to look at the best ways to serve the people and places where support is needed to elevate the quality of research and care,” said Nancy R. Daly, MS, MPH, chief executive officer, Conquer Cancer. “The Gateway Discovery Grant will play a vital role in our longstanding commitment to improving treatment for every cancer, every patient, everywhere.”

Letters of Intent for the Gateway Discovery Grant will be accepted through March 15, 2021, and the application deadline is August 16, 2021. To learn more or apply, please visit http://www.asco.org/gateway.

About Gateway for Cancer Research

Gateway for Cancer Research℠ is a nonprofit 501C(3) organization committed to funding practice-changing discoveries in cancer care by awarding grants to clinician-scientists advancing early stage clinical trials for cancers of all types, bringing breakthroughs to the bedside for patients facing a cancer diagnosis. Thanks to generous underwriting, 99 cents of every dollar Gateway receives directly funds Phase I and Phase II cancer clinical trials at leading research institutions around the world. Since 1991, Gateway has supported more than 180 clinical trials and funded over $90 million in transformational cancer research. Get involved today by visiting http://www.GatewayCR.org, like us on Facebook at facebook.com/demandcures and join the conversation on Twitter and Instagram at @DemandCures, #BeAGateway.

About Conquer Cancer

Conquer Cancer®, the ASCO Foundation, funds research into every facet of cancer to benefit every patient, everywhere. In 1964, seven oncologists created the American Society of Clinical Oncology (ASCO), now a global network of nearly 45,000 cancer professionals. As ASCO’s foundation, Conquer Cancer helps turn science into a sigh of relief for patients around the world by supporting groundbreaking research and education across cancer’s full continuum.

For more information, visit CONQUER.ORG.

Share article on social media or email:

Dallas Skyline Will Shine Purple for National Epilepsy Awareness Month


epilepsy; Stratus; Epilepsy Foundation; World Health Organization

Support the Fight to End Epilepsy

Stratus, the leader in home video electroencephalogram (EEG) testing, is partnering with the Epilepsy Foundation Texas and buildings in downtown Dallas to increase epilepsy awareness in honor of National Epilepsy Awareness Month. This Friday, November 6th, Bank of America Plaza and surrounding buildings will light up purple, the color that represents epilepsy awareness.

According to the World Health Organization, epilepsy is the most common serious brain disorder worldwide with no age, race, social class, national or geographic boundaries. Epilepsy is a seizure disorder. The seizures are caused by disturbances in the electrical activity of the brain and most of the time, the cause is unknown and there is no known cure for the disorder.

Irving based Stratus initiated the support of the downtown Dallas businesses to expand awareness about epilepsy and the fight to end it. “We are committed to helping those living with these disorders,” says Charlie Alvarez, CEO of Stratus. “Our commitment includes bringing high-quality, in-home video EEG testing to people across the U.S. living in both metropolitan and rural areas. Stratus’ company values also include supporting the overall health and well-being of our customers. We are thankful for the support of the downtown businesses.”

“We are so excited to see the Dallas buildings light up purple for National Epilepsy Awareness Month and are grateful for their support. An estimated 3.4 million people in the U.S. have been diagnosed with epilepsy and each year 150,000 more people are diagnosed. The mission of the Epilepsy Foundation is to lead the fight to overcome the challenges of living with epilepsy and to accelerate therapies to stop seizures, find cures, and save lives,” says Shannon Luck, Development Coordinator at the Epilepsy Foundation Texas. “We hope to continue this tradition of lighting up Dallas for National Epilepsy Awareness Month and look forward to getting more buildings involved in the lighting.”

For more information about National Epilepsy Awareness Month please visit epilepsy.com/NEAM.

For more information on how Stratus is helping people with seizures and seizure-like disorders please visit stratusneuro.com.

Share article on social media or email:

DNA BIOPHARM ® Leads National Bladder Awareness Month Initiatives Tied to FEMAXEEN®


News Image

We want women to have the ability to be open to talking about their incontinence and understand that FEMAXEEN® is a safe supplement regimen that will help to maintain a healthy bladder and most importantly, enjoy life without having to worry about leakage.

DNA® BIOPHARM (DNA®) announced an initiative to educate consumers about maintaining a healthy bladder and incontinence solutions during National Bladder Awareness Month. They recently launched their female urinary incontinence supplement, FEMAXEEN®, designed to maintain a healthy bladder, support urinary tract health, and improve women’s overall quality of life.

According to World Health Organization (WHO), the prevalence of urinary incontinence is twice as high in older women as in older men. Two leading factors that impact incontinence are stress and urge. While stress incontinence is the involuntary leaking of urine from exertion, coughing or sneezing, urge incontinence, involves a constellation of issues including frequency, urgency and leakage immediately preceded by urgency. With FEMAXEEN®, women can let go of incontinence and maintain a healthy bladder and urinary flow.

“Raising bladder health awareness and encouraging women to talk about their bladder health is a critical first step in eliminating the stigma associated with incontinence,” said Oscar del Cid, President and CEO of DNA®. “We want women to have the ability to be open to talking about their incontinence and understand that FEMAXEEN® is a safe supplement regimen that will help to maintain a healthy bladder and most importantly, enjoy life without having to worry about leakage.”

FEMAXEEN® has active ingredients that helps women improve their quality of life by alleviating stress, urge and mixed urinary incontinence. Pumpkin seed extract is one of the key ingredients that will help support lower urinary tract health and keep control of urine flow.

In celebration of National Bladder Awareness Month, FEMAXEEN® is offering 15% off purchases with promo code BLADDER15.

To purchase FEMAXEEN® visit https://femaxeen.com.

About FEMAXEEN®

FEMAXEEN® is distributed by DNA BIOPHARM ® as s dietary supplement that supports lower urinary tract health. A complete solution for women’s incontinence, FEMAXEEN® has been tested and evaluated through a randomized, double-blind, placebo-controlled study with findings citing a 45.3% reduction in incontinence within two months. Now available in the U.S., FEMAXEEN® can be purchased without a prescription.

About DNA BIOPHARM ®

Founded in 1992, DNA® has done business in over 25 countries, covering six continents, and currently operating in America (Miami), Mexico (Mexico City) Europe (Budapest, Hungary), and Africa (Cape Town, South Africa). In 2013, DNA Mexico became one of the largest distributors of The Day After Pill after introducing the pill in 2003 and selling about 30,000,000 units within a 10-year period. Today, DNA® continues to manufacture and distribute a comprehensive line of products that target a wide range of health issues ranging from immune deficiency, psoriasis, acne, adrenal stability, incontinence, and more. DNA® is poised to continue great leaps forward with their tradition of growth, quality, and service worldwide.

Share article on social media or email:

PathAI and Gilead Report Data from Machine Learning Model Predictions of Liver Disease Progression and Treatment Response at AASLD’s The Liver Meeting 2020


PathAI, a global provider of AI-powered technology applied to pathology research, today announced the results of a research collaboration with Gilead that retrospectively analyzed liver biopsies from participants in clinical trials evaluating treatments for NASH or CHB (1). Using digitized hematoxylin and eosin (H&E)-, picrosirius red-, and trichrome-stained biopsy slides, PathAI’s machine learning (ML) models were able to accurately predict changes in features traditionally used as markers for liver disease progression in clinical practice and clinical trials, including fibrosis, steatosis, hepatocellular ballooning, and inflammation. The new results will be presented in an oral presentation and 4 poster sessions at The Liver Meeting Digital Experience™ (TLMdX) that will be held from November 13-16, 2020.

The data builds upon PathAI’s previous success in retrospectively staging liver biopsies from clinical trials by showing that ML models may uncover patterns of histological features that correlate with disease progression or treatment response. Furthermore, ML models were able to estimate the hepatic venous pressure gradient (HVPG) in study subjects with NASH related cirrhosis and quantify fibrosis heterogeneity from digitized slides, which are measures that are not reliably captured by traditional pathology methods. After appropriate clinical validation, these new tools could be useful in staging disease more accurately than can be done with current approaches.

“We continue to use machine learning to advance our understanding of liver diseases, including NASH and hepatitis B, as a foundation for developing new methods to track disease progression and assess response to therapeutics,” said PathAI co-founder and Chief Executive Officer Andy Beck MD, PhD. “Our long-standing partnership with Gilead continues to demonstrate the power of AI-based pathology to support development efforts to bring new therapies to patients.”

Highlights include:


  • Development of a sensitive ML-based scoring system (DELTA Liver Fibrosis Score) to measure changes in liver fibrosis in response to cilofexor and/or firsocostat treatment in the Phase 2b ATLAS trial of combination therapies to treat advanced fibrosis due to NASH
  • Integration of ML-based histologic predictions with hepatic gene expression data obtained using RNA-seq was used to identify a combination of genes and histological features that correlate with disease progression in subjects with advanced fibrosis due to NASH
  • ML-models were trained to generate a score for prediction of HVPG using biopsies and centrally-read HVPG measurements from study subjects with compensated cirrhosis due to NASH
  • Using biopsies from clinical trials for tenofovir disoproxil fumarate (TDF) for CHB, ML-models identified liver cell- and tissue-level morphologies apparent at baseline (BL) and Year 5 of treatment that correlate with changes in viral biomarkers
  • In the subset of clinical trial participants with CHB that continued to have elevated serum alanine aminotransferase (ALT) despite virologic suppression, ML-models identified histological features strongly suggestive of underlying fatty liver disease

“Data presented at AASLD demonstrate the potential of machine learning approaches to improve our assessment of liver disease severity, reduce the variability of human interpretation of liver biopsies, and identify novel features associated with disease progression,” said Rob Myers, MD, Vice President, Liver Inflammation/Fibrosis, Gilead Sciences. “We are proud of our ongoing partnership with PathAI and look forward to continued collaboration toward our shared goals of enhancing research efforts and improving outcomes of patients with liver disease.”

The antiviral drug TDF effectively suppresses hepatitis B virus in patients with CHB, but a small subset of patients have persistently elevated serum ALT despite virologic suppression. ML-models were applied to biopsy data from registrational studies of TDF to examine this small subgroup of non-responders. Analyses of the ML-model predicted histologic features showed that persistently elevated ALT after five years of TDF treatment is associated with a higher steatosis score at BL and increases in steatosis during follow-up. These data suggest that subjects with elevated ALT despite TDF treatment may have underlying fatty liver disease that impacts biochemical response.

Machine Learning Enables Quantitative Assessment of Histopathologic Signatures Associated with ALT Normalization in Chronic Hepatitis B Patients Treated with Tenofovir Disoproxil Fumarate (TDF) Oral Abstract #18

ML-models were deployed on biopsies from registrational trials of TDF in CHB to identify cellular and tissue-based phenotypes associated with HBV DNA and hepatitis B e-antigen (HBeAg). The study demonstrated that proportionate areas of ML-model-predicted hepatocellular ballooning at BL and Yr 5, and lobular inflammation at Yr 5 were higher in subjects that did not achieve virologic suppression. In addition, lymphocyte density across the tissue and within regions of lobular inflammation correlated with HBeAg loss, supporting the importance of an early immune response for viral clearance.

Machine Learning Based Quantification of Histology Features from Patients Treated for Chronic Hepatitis B Identifies Features Associated with Viral DNA Suppression and dHBeAg Loss Poster Number #0848

Standard manual methods for staging liver fibrosis have limited sensitivity and reproducibility. Application of a ML-model to evaluate changes in fibrosis in response to treatment in the STELLAR and ATLAS trials enabled development of the DELTA (Deep Learning Treatment Assessment) Liver Fibrosis Score. This scoring method accounts for the heterogeneity in fibrosis severity that can be detected by ML-models and reflects changes in fibrotic patterns that occur in response to treatment. Application of the DELTA Liver Fibrosis Score to biopsies from the Phase 2b ATLAS trial demonstrated a reduction in fibrosis in response to treatment with the investigational combination of cilofexor and firsocostat that was not detected by standard staging methods.

Validation of a Machine Learning-Based Approach (DELTA Liver Fibrosis Score) for the Assessment of Histologic Response in Patients with Advanced Fibrosis Due to NASH Poster Number #1562

Integration of tissue transcriptomic data with histologic information is likely to reveal new insights into disease. Using liver tissue obtained during the STELLAR trials evaluating NASH subjects with advanced fibrosis, RNA-seq-generated, tissue-level gene expression profiles were integrated with ML-predicted histology. This analysis revealed five key genes strongly correlated with proportionate areas of portal inflammation and bile ducts, features that are themselves predictive of disease progression in NASH. High levels of expression of these genes was associated with an increased risk of progression to cirrhosis in subjects with bridging (F3) fibrosis (hazard ratio [HR] 2.1; 95% CI 1.25, 3.49) and liver-related clinical events among those with cirrhosis (HR 4.05; 95% CI 1.4, 14.36).

Integration of Machine Learning-Based Histopathology and Hepatic Transcriptomic Data Identifies Genes Associated with Portal Inflammation and Ductular Proliferation as Predictors of Disease progression in Advanced Fibrosis Due to NASH Poster Number #595

The severity of portal hypertension as assessed by HPVG predicts the risk of hepatic complications in patients with liver disease but is not simple to measure. ML-models were trained on images of 320 trichrome-stained liver biopsies from a phase 2b trial of investigational simtuzumab in subjects with compensated cirrhosis due to NASH to recognize patterns of fibrosis that correlate with centrally-read HVPG measurements. Deployed on a test set of slides, ML-calculated HVPG scores strongly correlated with measured HVPG and could discriminate subjects with clinically-significant portal hypertension (HVPG ≥10 mm Hg).

A Machine Learning Model Based on Liver Histology Predicts the Hepatic Venous Pressure Gradient (HVPG) in Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Poster Number #1471

(1) Trials include STELLAR, ATLAS, and NCT01672879 for investigation of NASH therapies, and registrational studies GS-US-174-102/103 for tenofovir disoproxil fumarate [TDF] for CHB.

About PathAI

PathAI is a leading provider of AI-powered research tools and services for pathology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning. Based in Boston, PathAI works with leading life sciences companies and researchers to advance precision medicine. To learn more, visit pathai.com.

Share article on social media or email:

DPB Awarded Boston magazine’s Top Dentists™ 2020


Entire Dental Team At Dental Partners of Boston

Dental Team At Dental Partners of Boston

Proper comprehensive planning and detailed and careful execution in conjunction with adequate healing times will obtain results which will exceed anyone’s expectations. – Dr. Guzman

Dental Partners of Boston (DPB) is the winner of Top Dentists™ 2020 for many dental specialties, affirming its place as a leading dental practice in Boston.

All the dentists at Dental Partners of Boston have won Boston magazine’s Top Dentists™ 2020 award. The award is an annual list that Boston magazine releases on the field’s best dentists. The publication selected thirteen DPB dentists for the award, highlighting the practice’s commitment to excellence.

Sergio A. Guzman D.M.D, M.S.D, the Managing Member of Dental Partners of Boston, said that success comes down to the synergy of DPB’s team approach.

“Our consistent results are based on all of us working together with the same goal in mind. The success of our group practice is only possible by the addition of all the individual successes of our doctors and team.”

When asked what set DPB apart from other dental practices in the greater Boston area, Dr. Guzman pointed to the convenience of its two locations and its team of highly experienced dentists who worked together to deliver a superior patient experience.

DPB has spent more than fifty years carefully building its relationships with members of the local community. The constant interaction between patients and doctors is fundamental to its approach.

Speaking on behalf of the team, Dr. Guzman said, “We are honored to be recognized by our peers, and it is a great incentive to all of us to always reach for the best outcome. It pushes us to be true to our commitment to excellence in dental care.”

When looking for great dentists, DPB has some advice for patients. Dr. Guzman says that patients should visit practices that commit to excellence in all aspects of their work. Essential considerations include a multi-disciplinary team, advanced experience, high proficiency, exceptional customer service, and convenient locations and hours.

Dr. Guzman would like patients to understand that, “Fast dentistry most times cannot generate amazing results. He adds that, “Proper comprehensive planning and detailed and careful execution in conjunction with adequate healing times will obtain results which will exceed anyone’s expectations.” Fast dentistry often forces compromises that lead to poorer outcomes.

Dental Partners of Boston currently offers various cosmetic dental treatments, including porcelain veneers, cosmetic dental bonding, dental implants, Invisalign® invisible braces, all-porcelain dental crowns, tooth-colored fillings, and Zoom! Teeth Whitening. DPB also offers a range of general and preventive dental services, plus specialty dental care, including LANAP treatment for periodontal disease.

Click the link to see each dentist at DPB that won Boston magazine’s Top Dentists™ 2020.

For more information on DPB, its team, and the services it offers, please visit https://www.dentalpartnersofboston.com/. For their Prudential Center office, call (617) 259-1100, or for their Charles River office, call (617) 523-4555. Interested parties can visit in-person at Prudential Center 800 Boylston Street., 2nd Floor, Boston, MA 02199 or the office at Charles River 50 Staniford Street #303, Boston, MA 02114.

Share article on social media or email:

Suffering with Lower Back Pain? Typical Causes Lower Back Pain


Dr. Kaliq Chang

If your lower back pain doesn’t get better within 6 to 12 weeks, see a doctor for a more detailed diagnostic process to pinpoint the cause.

If your Grandpa, Uncle Bob or Sister Sue dealt with lower back pain – especially as they got older – you may feel powerless to prevent the highly common problem in yourself. But the good news is that many typical triggers of lower back pain result from lifestyle choices we can change, according to Kaliq Chang, MD, of Atlantic Spine Center.

There’s no question that lower back pain is prevalent: More than 8 in 10 American adults will experience the condition at some point in their lives, according to the National Institutes of Health. But Dr. Chang, an interventional pain management specialist, is quick to point out that most cases of lower back pain are temporary, and only a few factors leading to it aren’t controllable.

“Age and family history can’t be modified, of course” he explains. “And so-called ‘mechanical injury’ to muscles or tendons, or to tissues surrounding the spine’s bony vertebrae, can result from sports mishaps, auto accidents, falls or other unpredictable situations. But our lifestyle plays a major role in either triggering lower back pain or preserving our lower spine health.”

Common causes

What are some of the most common triggers of lower back pain we can control? According to Dr. Chang, they include:

Exercise: Whether you exercise too little or too much, either can lead to lower back pain. Being a couch potato doesn’t properly strengthen back muscles, but overuse injuries can also take a toll. “Exercise is generally great for your back, but pay attention to signals that you may be overdoing it,” he says.

Sitting: A lot of us sit at a desk all day, but doing so places more pressure on spinal discs and vertebrae than standing or walking. “Ideally, you’ll alternate periods of sitting with periods of getting up, stretching, and walking around during your workday,” Dr. Chang advises.

Smoking: This one’s simple – don’t do it, or stop if you do. Nicotine is known to reduce healthy blood flow around the body, including to vertebrae and spinal discs.

Core strength: This goes back to exercise, but speaks also to the types of movements that strengthen core muscles in the hips, back, abdomen and pelvis. All of these muscles help support the spine and prevent injuries, Dr. Chang says. “Lunges, planks, squats, yoga and

Pilates can boost core strength immensely,” he adds.

Weight: Keeping extra pounds away is important for several health reasons, but also because the lower back area bears a disproportionate share of the strain. “Even 10 extra pounds of weight, especially when concentrated in the belly area, can pull your spine out of alignment and lead to lower back pain,” Dr. Chang notes.

Stress levels: Sure, getting stressed out sure can seem uncontrollable at times. But research has long linked psychological stress with physical effects such as back pain by creating tremendous muscle tension in the lower spine area, Dr. Chang says.

Tips on treatment

As noted earlier, most cases of lower back pain resolve within days to weeks, Dr. Chang says, and don’t require anything more than simple at-home measures to find relief. These treatments include over-the-counter pain relievers such as ibuprofen or naproxen; rest; applying ice or heat; and gentle stretching.

But if your lower back pain doesn’t get better within 6 to 12 weeks, see a doctor for a more detailed diagnostic process to pinpoint the cause. Getting a prompt medical evaluation becomes even more important if your back pain is joined by tingling or numbness in the legs or feet, or if your pain awakens you at night, Dr. Chang says.

“Advanced technology to diagnose the causes of lower back pain, such as MRI or CT scans, offer a huge advantage toward addressing the pain and getting patients back to doing all their favorite activities,” he says. “Just don’t feel helpless or powerless to prevent or treat lower back pain.”

Atlantic Spine Center is a nationally recognized leader for endoscopic spine surgery with several locations in NJ and NYC. http://www.atlanticspinecenter.com, http://www.atlanticspinecenter.nyc

Kaliq Chang, MD, is an interventional pain management specialist, double board-certified in interventional pain management and anesthesiology, at Atlantic Spine Center.

Share article on social media or email: